SCHEMBL4254924

SCHEMBL4254924

CCCCCC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)[C@H](OC(=O)CCCCC)C[C@@H]12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.59
KMT2A Q03164 5/20 0.59
MEN1 O00255 3/20 0.59
THRB P10828 1/20 0.59
LMNA P02545 6/20 0.58
SMN1; SMN2 Q16637 5/20 0.58
ESR1 P03372 4/20 0.58
ADORA3 P0DMS8 3/20 0.58
ATM Q13315 3/20 0.58
TP53 P04637 3/20 0.58
CYP3A4 P08684 3/20 0.58
PGR P06401 2/20 0.58
AR P10275 2/20 0.58
CHRM1 P11229 2/20 0.58
TBXA2R P21731 2/20 0.58
USP2 O75604 2/20 0.58
ALOX15 P16050 2/20 0.58
POLB P06746 1/20 0.58
PTGS1 P23219 1/20 0.58
PDE3A Q14432 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10349557 0.99 MAPT (0.58) MAPTKMT2AMEN1THRBLMNA
SCHEMBL10349240 0.97 MAPT (0.61) MAPTKMT2AMEN1THRBLMNA
SCHEMBL10349791 0.97 MAPT (0.61) MAPTKMT2AMEN1THRBLMNA
SCHEMBL10349238 0.94 MAPT (0.61) MAPTKMT2AMEN1THRBLMNA
SCHEMBL4254922 0.89 MAPT (0.58) MAPTKMT2AMEN1THRBLMNA
SCHEMBL6547189 0.89 MAPT (0.58) MAPTKMT2AMEN1THRBLMNA
SCHEMBL10349423 0.89 MAPT (0.74) MAPTKMT2AMEN1THRBLMNA
SCHEMBL10710638 0.88 MAPT (0.57) MAPTKMT2AMEN1THRBLMNA
SCHEMBL4585647 0.88 MAPT (0.62) MAPTKMT2AMEN1THRBLMNA
SCHEMBL10361012 0.86 LMNA (0.60) MAPTKMT2AMEN1THRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452175-B2 Pregnancy hormone combination for treatment of autoimmune diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-09-27 US claimed
US-20160082017-A1 ESTRIOL THERAPY FOR MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-24 US claimed
EP-0196268-B1 ESTRIOL ESTERS SCHERING AKTIENGESELLSCHAFT (DE) 1990-06-27 EP claimed
US-4738957-A ESTROGEN THERAPY SCHERING AKTIENGESELLSCHAFT (DE) 1988-04-19 US claimed
EP-0196268-A2 Estriol esters SCHERING AKTIENGESELLSCHAFT (DE) 1986-10-01 EP claimed
US-20260014080-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF VAN BOGAERT GINA (BE) 2026-01-15 US disclosed
EP-3277285-B1 ESTRIOL FOR REDUCING CORTICAL GRAY MATTER ATROPHY UNIV CALIFORNIA (US) 2024-07-17 EP disclosed
US-11865122-B2 Estrogen therapy for brain gray matter atrophy and associated disability THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-01-09 US disclosed
WO-2023223235-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF PURNA PHARMACEUTICALS NV (BE) 2023-11-23 WO disclosed
EP-3137087-B1 ESTROGEN COMBINATION FOR TREATMENT OF MULTIPLE SCLEROSIS UNIV CALIFORNIA (US) 2023-09-06 EP disclosed
EP-3137088-B1 PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY FOR THE TREATMENT OF MULTIPLE SCLEROSIS UNIV CALIFORNIA (US) 2023-08-30 EP disclosed
EP-3200802-B1 COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION UNIV CALIFORNIA (US) 2023-07-12 EP disclosed
WO-2016036719-A1 ESTROGEN THERAPY FOR BRAIN GRAY MATTER ATROPHY AND ASSOCIATED DISABILITY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-03-10 WO disclosed
WO-2015168000-A1 ESTROGEN COMBINATION FOR TREATMENT OF MULTIPLE SCLEROSIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-11-05 WO disclosed
WO-2015168002-A1 PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-11-05 WO disclosed
US-20090082322-A1 Gender Differences in Experimental Aortic Aneurysm Formation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2009-03-26 US disclosed
WO-2006053172-A2 THE USE OF ESTRIOL AND OTHER ESTRANES, ESTROGENS AND ESTROGEN RECEPTOR ACTIVE COMPOSITIONS IN THE TREATMENT OF PSORIASIS AND OTHER AUTOIMMUNE DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-05-18 WO disclosed
WO-2006042172-A2 GENDER DIFFERENCES IN EXPERIMENTAL AORTIC ANEURYSM FORMATION THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2006-04-20 WO disclosed
US-20050209208-A1 Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-09-22 US disclosed
EP-0196268-A2 Estriol esters SCHERING AKTIENGESELLSCHAFT (DE) 1986-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209208-A1 Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders SHBG, ESR2, ESR1 MAPT 1240/4885KMT2A 4020/4885MEN1 1165/4885
US-20260014080-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF NR5A1, SHBG, GNRHR MAPT 4293/4885KMT2A 3205/4885MEN1 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.